MyFinsight
Home
Blog
About
Contact
Download
Download image
Unrealized gain (loss) on
foreign currency...
$157,897
(180.63%↑ Y/Y)
Total comprehensive
income (loss)
-$347,166
(-103.14%↓ Y/Y)
Total other
comprehensive income (loss)
$157,897
(180.63%↑ Y/Y)
Net (loss) income
-$505,063
(-104.48%↓ Y/Y)
Income tax benefit
-$34,793
(57.14%↑ Y/Y)
Gain (loss) on fair
value adjustments
$435,193
(144.56%↑ Y/Y)
Research and development
incentive award
-$341,951
(-6642.01%↓ Y/Y)
Interest income, net
$186,171
(1361.20%↑ Y/Y)
(loss) income before
income taxes
-$539,856
(-104.83%↓ Y/Y)
Total other income
(expense)
$671,793
(184.37%↑ Y/Y)
(loss) gain on foreign
currency transactions
-$291,522
(-268.56%↓ Y/Y)
(loss) income from
operations
-$1,211,649
(-110.12%↓ Y/Y)
Total operating
expenses
$1,211,649
(-59.92%↓ Y/Y)
Research and development
-$518,168
(-132.06%↓ Y/Y)
General and
administrative
$1,687,403
(19.95%↑ Y/Y)
Restructuring costs
$42,414
Back
Back
Income Statement
Neuphoria Therapeutics Inc. (NEUP)
Neuphoria Therapeutics Inc. (NEUP)
source: myfinsight.com